This antibody detects endogenous levels of Chk1 only when phosphorylated at Serine 280.
Purification
Affinity Chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Immunogen
The antiserum was produced against synthesized phosphopeptide derived from human Chk1 around the phosphorylation site of Serine 280 (V-T-Sp-G-G).
Western Blot: 1/500approx. 1/1000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS (without Mg2+ and Ca2+), pH 7.4 containing 150 mM NaCl, 0.02 % Sodium Azide and 50 % Glycerol.
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
-20 °C
Storage Comment
Store the antibody (in aliquots) at-20 °C.
Target
CHEK1
(Checkpoint Kinase 1 (CHEK1))
Alternative Name
CHK1
Background
One mechanism by which checkpoints maintain the fidelity of cell cycle events is through blocking mitosis in response to unreplicated or damaged DNA. In most species this occurs through inhibiting activation of the cyclic dependent kinase Cdc2, which regulates entry into mitosis. Chk1, a kinase involved in the DNA damage checkpoint response can phosphorylate Cdc25C an activator of Cdc2. It is hypothesized that Chk1 induces serine 216 phosphorylation of Cdc25C and subsequent 14-3-3 binding negatively regulated Cdc25C, thus preventing it from activating Cdc2.Synonyms: CHEK-1, CHEK1, CHK1 checkpoint homolog, Serine/threonine-protein kinase Chk1